Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management

Clémence Basse; Aurelie Swalduz; Matteo Giaj Levra; Nicolas Girard; Jordi Remon; Denis Moro-Sibilot

doi:10.1016/j.bulcan.2020.04.018

Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management

Titre traduit de la contribution: Immunothérapie des cancers bronchiques non à petites cellules métastatiques, de la première ligne à la résistance et sa prise en charge

Clémence Basse, Aurelie Swalduz, Matteo Giaj Levra, Nicolas Girard, Jordi Remon, Denis Moro-Sibilot

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

2 Citations (Scopus)

Résumé

Immunotherapy alone or in combination with chemotherapy is now an integral part of the treatment of metastatic NSCLC. This treatment is transforming the management of these cancers, with 20–30% of patients achieving long survival. However, disease progression under treatment is still the rule for the majority of patients, raising problems both in understanding its mechanisms and in subsequent appropriate management. This study examines current therapeutic options and proposes solutions to circumvent resistance to immunotherapy. The mechanisms of resistance to these treatments is also analysed.

Titre traduit de la contribution	Immunothérapie des cancers bronchiques non à petites cellules métastatiques, de la première ligne à la résistance et sa prise en charge
langue originale	Anglais
Pages (de - à)	779-791
Nombre de pages	13
journal	Bulletin du Cancer
Volume	107
Numéro de publication	7-8
Les DOIs	https://doi.org/10.1016/j.bulcan.2020.04.018
état	Publié - 1 juil. 2020
Modification externe	Oui

Accès au document

10.1016/j.bulcan.2020.04.018

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{66add702395744a29279f97a0b29160d,

title = "Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management",

abstract = "Immunotherapy alone or in combination with chemotherapy is now an integral part of the treatment of metastatic NSCLC. This treatment is transforming the management of these cancers, with 20–30% of patients achieving long survival. However, disease progression under treatment is still the rule for the majority of patients, raising problems both in understanding its mechanisms and in subsequent appropriate management. This study examines current therapeutic options and proposes solutions to circumvent resistance to immunotherapy. The mechanisms of resistance to these treatments is also analysed.",

keywords = "Chemotherapy, Immunotherapy, Lung cancer, Mechanisms of resistance",

author = "Cl{\'e}mence Basse and Aurelie Swalduz and Levra, {Matteo Giaj} and Nicolas Girard and Jordi Remon and Denis Moro-Sibilot",

note = "Publisher Copyright: {\textcopyright} 2020 Soci{\'e}t{\'e} Fran{\c c}aise du Cancer",

year = "2020",

month = jul,

day = "1",

doi = "10.1016/j.bulcan.2020.04.018",

language = "English",

volume = "107",

pages = "779--791",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "7-8",

}

TY - JOUR

T1 - Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management

AU - Basse, Clémence

AU - Swalduz, Aurelie

AU - Levra, Matteo Giaj

AU - Girard, Nicolas

AU - Remon, Jordi

AU - Moro-Sibilot, Denis

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Immunotherapy alone or in combination with chemotherapy is now an integral part of the treatment of metastatic NSCLC. This treatment is transforming the management of these cancers, with 20–30% of patients achieving long survival. However, disease progression under treatment is still the rule for the majority of patients, raising problems both in understanding its mechanisms and in subsequent appropriate management. This study examines current therapeutic options and proposes solutions to circumvent resistance to immunotherapy. The mechanisms of resistance to these treatments is also analysed.

AB - Immunotherapy alone or in combination with chemotherapy is now an integral part of the treatment of metastatic NSCLC. This treatment is transforming the management of these cancers, with 20–30% of patients achieving long survival. However, disease progression under treatment is still the rule for the majority of patients, raising problems both in understanding its mechanisms and in subsequent appropriate management. This study examines current therapeutic options and proposes solutions to circumvent resistance to immunotherapy. The mechanisms of resistance to these treatments is also analysed.

KW - Chemotherapy

KW - Immunotherapy

KW - Lung cancer

KW - Mechanisms of resistance

UR - http://www.scopus.com/inward/record.url?scp=85086161111&partnerID=8YFLogxK

U2 - 10.1016/j.bulcan.2020.04.018

DO - 10.1016/j.bulcan.2020.04.018

M3 - Review article

C2 - 32532420

AN - SCOPUS:85086161111

SN - 0007-4551

VL - 107

SP - 779

EP - 791

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 7-8

ER -